Please ensure Javascript is enabled for purposes of website accessibility
Peter Stephens

Peter Stephens


Peter is a Healthcare Specialist at The Motley Fool.

Recent articles

This Is Dividend Stock Johnson & Johnson’s Major Weakness

Although diversification can sometimes be a strength, it can also prove to be a double-edged sword in the long run. Here’s how.

Johnson & Johnson's 3 Major Strengths

What are the three key reasons why J&J could be a top performer in the future?

Can J&J's Pharma Segment Deliver Meaningful Growth?

In the final part of a three-part series, I take a deep dive into J&J's pharmaceuticals segment and ask whether it's as attractive as many investors believe.

Don't Underestimate J&J's Best-Known Products

In the second of a three-part series I take a closer look at J&J's (NYSE: JNJ) consumer segment to find out if it could make the stock take off.

Is J&J's Forgotten Half About to Take Off?

In the first of a three-part series, I put Johnson & Johnson's medical devices and diagnostics segment under the investment microscope.

Why Philip Morris Could Be a Winning Stock

Philip Morris could be a strong performer in future. Here's why.

Is Novartis' Strategy a Winning One?

Novartis has changed to a new strategy. Is it likely to be a successful one?

Is Procter & Gamble a Buy at Current Levels?

With shares disappointing in recent years, is Procter & Gamble now attractive?

Better Buy: GlaxoSmithKline, AbbVie, or Merck?

Shares in GlaxoSmithKline have underperformed the index in recent years. Does this mean the stock is undervalued?

Does Bristol-Myers Squibb Offer Good Value?

Having had a strong performance in recent years, does Bristol-Myers Squibb still offer good value for your money at current price levels?

Can Pfizer Outperform in 2014?

After tracking the index for five years, Pfizer could be worth buying. Here's why.

Can AbbVie Continue Its Bull Run?

After an impressive share price performance since it listed, is AbbVie still worth buying?

Better Buy: Johnson & Johnson, Pfizer, or Bristol-Myers Squibb?

Is the relative stability provided by Johnson & Johnson's diversified business model a major advantage when compared to Pfizer and Bristol-Myers Squibb?

Can Eli Lilly Continue its Bull Run?

Despite some disappointing news, Eli Lilly's stock has made a strong start to 2014. Can it keep going?

Bristol-Myers Squibb: More Than Just a Relief Rally?

Shares in Bristol-Myers Squibb performed relatively positively last week. Can they keep it going?

Is Merck a Buy at Current Price Levels?

After a strong recent run, are shares in Merck (NYSE: MRK) still worth buying?

Can Merck Keep Its Bull Run Going?

Shares in Merck have made a strong start to 2014. Can they keep going?

Has Celgene Corporation Run Out of Steam in 2014?

After an awesome 2013, Celgene (NASDAQ: CELG) has made a bad start to the year. Can it recover?

Can Bristol-Myers Squibb Keep Its Bull Run Going in 2014?

The year 2013 was a great one for Bristol-Myers Squibb (NYSE: BMY); 2014 could also be a strong year due to a potential catalyst.

Can Roche Keep Its Bull Run Going?

Despite mixed recent news flow, Roche remains a company with significant potential.